Roots
Analysis is pleased to announce the publication of its recent study, titled, “China Biopharmaceutical Contract
Manufacturing Market,
2021-2030.”
Owing
to benefits, such as reduced manufacturing costs, availability of cheap and
skilled labor, and a supportive regulatory landscape, biopharmaceutical
developers from across the globe, are increasingly outsourcing their
manufacturing operations to China based CMOs. Further, in order to meet the
growing demand for their services, Chinese CMOs are actively consolidating /
expanding their capabilities through partnerships and / or dedicated expansion
initiatives.
